Keytruda shadows GSK's Jemperli in endometrial cancer

GSK had just two months to celebrate the positive phase 3 result with its checkpoint inhibitor Jemperli as a first-line therapy for endometrial cancer, before Merck &

Merck's Keytruda demonstrates adjuvant use in kidney cancer

Merck & Co has announced interim data from its pivotal Phase 3 KEYNOTE-564 trial evaluating immunotherapy Keytruda for the potential adjuvant treatment of patients with renal cell carci

Study resurrects Merck’s hopes for Keytruda in breast cancer

Merck gets FDA nod for new antibiotic, but says use with car...

Merck claims a brace of head and neck cancer approvals

Merck & Co/MSD has done the double in head and neck cancer with a pair of FDA approvals for Keytruda in newly diagnosed patients on the same day.